Department of Microbiology, Molecular Genetics and Immunology, The University of Kansas Medical Center, Kansas City, KS 66160, United States.
Vaccine. 2012 Apr 19;30(19):2956-62. doi: 10.1016/j.vaccine.2012.02.050. Epub 2012 Mar 2.
Increasing the safety and the efficacy of existing HIV vaccines is one of the strategies that could help to promote the development of a vaccine for human use. We developed a HIV DNA vaccine (Δ4-SHIVKU2) that has been shown to induce potent polyfunctional HIV-specific T cell responses following a single dose immunization of mice and macaques. Δ4-SHIVKU2 also induced protection when immunized macaques were challenged with homologous pathogenic viruses. In the present study, our aim was to examine whether a chimeric HIV DNA vaccine (CAL-Δ4-SHIVKU2) whose genome is driven by the LTR of the goat lentivirus, caprine arthritis encephalitis (CAEV) expresses efficiently the vaccine antigens and induces potent immune responses in animal models for HIV vaccine. Data of radioimmunoprecipitation assays clearly show that this chimeric genome drives efficient expression of all HIV antigens in the construct. In addition, evaluation of the p24 Gag protein in the supernatant of HEK-293-T cells transfected in parallel with Δ4-SHIVKU2 and CAL-Δ4-SHIVKU2 showed no difference suggesting that these two LTRs are inducing equally the expression of the viral genes. Immunization of mice and macaques using our single dose immunization regimen resulted in induction of similar IFN-γ ELISPOT responses in Δ4-SHIVKU2- and CAL-Δ4-SHIVKU2-treated mice. Similar profiles of T cell responses were also detected both in mice and macaques when multiparametric flow cytometry analyses were performed. Since CAEV LTR is not dependent of Tat to drive viral gene expression and is not functional for integration with HIV integrase, this new vector increases the safety and efficacy of our vaccine vectors and vaccination strategy.
提高现有 HIV 疫苗的安全性和有效性是促进人类使用疫苗发展的策略之一。我们开发了一种 HIV DNA 疫苗(Δ4-SHIVKU2),该疫苗在单次免疫小鼠和猕猴后可诱导强烈的多功能 HIV 特异性 T 细胞反应。Δ4-SHIVKU2 还在免疫猕猴受到同源致病性病毒攻击时诱导了保护。在本研究中,我们的目的是检查一种嵌合 HIV DNA 疫苗(CAL-Δ4-SHIVKU2),其基因组由山羊慢病毒、山羊关节炎脑炎(CAEV)的 LTR 驱动,是否能有效地表达疫苗抗原并在 HIV 疫苗的动物模型中诱导强烈的免疫反应。放射免疫沉淀分析的数据清楚地表明,该嵌合基因组在构建体中有效地表达了所有 HIV 抗原。此外,评估在与Δ4-SHIVKU2 和 CAL-Δ4-SHIVKU2 平行转染的 HEK-293-T 细胞上清液中的 p24 Gag 蛋白表明,这两个 LTR 同样诱导病毒基因的表达。使用我们的单次免疫方案免疫小鼠和猕猴,在Δ4-SHIVKU2 和 CAL-Δ4-SHIVKU2 处理的小鼠中诱导出类似的 IFN-γ ELISPOT 反应。当进行多参数流式细胞术分析时,在小鼠和猕猴中也检测到了类似的 T 细胞反应谱。由于 CAEV LTR 不依赖 Tat 驱动病毒基因表达,并且不能与 HIV 整合酶整合,因此这种新载体提高了我们疫苗载体和接种策略的安全性和有效性。